Share on StockTwits

NuVasive (NASDAQ:NUVA) EVP Russell Powers sold 9,526 shares of the stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $35.00, for a total transaction of $333,410.00. Following the completion of the transaction, the executive vice president now directly owns 43,281 shares in the company, valued at approximately $1,514,835. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of research firms have recently commented on NUVA. Analysts at Needham & Company LLC downgraded shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Wednesday, May 21st. They now have a $40.00 price target on the stock. Separately, analysts at Canaccord Genuity cut their price target on shares of NuVasive from $51.00 to $48.00 in a research note on Wednesday, April 30th. They now have a “buy” rating on the stock. Finally, analysts at Summer Street upgraded shares of NuVasive from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 30th. They now have a $42.00 price target on the stock. Seven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $39.26.

NuVasive (NASDAQ:NUVA) traded down 1.23% during mid-day trading on Tuesday, hitting $34.865. The stock had a trading volume of 361,487 shares. NuVasive has a one year low of $22.44 and a one year high of $39.89. The stock has a 50-day moving average of $33.7 and a 200-day moving average of $35.0. The company’s market cap is $1.625 billion.

NuVasive (NASDAQ:NUVA) last released its earnings data on Tuesday, April 29th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.06. The company had revenue of $177.50 million for the quarter, compared to the consensus estimate of $171.30 million. During the same quarter in the previous year, the company posted $0.26 earnings per share. The company’s revenue for the quarter was up 11.3% on a year-over-year basis. On average, analysts predict that NuVasive will post $1.09 earnings per share for the current fiscal year.

NuVasive, Inc is a medical device company, that focuses on developing minimally disruptive surgical products and procedures for the spine.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.